A Phase 1b, Single-Arm, Open Label Study to Evaluate the Safety and Efficacy of TRU-016 in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Status
Active
Cancer Type
Leukemia
Trial Phase
Phase I
Eligibility
18 and over, Male and Female
Study Type
Treatment
NCD ID
NCT01644253
Protocol IDs
16009 (primary)
Study Sponsor
Emergent Product Development Seattle, LLC

Summary

The purpose of this study is to evaluate the safety and efficacy of TRU-016 when when administered in combination with rituximab in patients with previously untreated chronic lymphocytic leukemia (CLL).